Bondrova®

Bondrova®

Ibandronate Sodium

150 mg Tablet
3 mg/ 3 ml IV Injection (Pre-filled Syringe)
150 mg + 600 mg & 400 IU Pro Tablet

Antiosteoporotic

Osteoporosis causes the body to remove more bone than it replaces. This means that bones get weaker. Weak bones are more likely to break. Osteoporosis is a bone disease that is quite common in women after menopause. It also affects men. At first, osteoporosis has no symptoms, but people with osteoporosis may develop loss of height and are more likely to break (fracture) their bones, especially the back (spine), wrist, and hip bones. Osteoporosis can be prevented, and with proper therapy it can be treated. Ibandronic acid inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to a progressive gain in bone mass. The absorption of ibandronate occurs in the upper gastrointestinal tract. After absorption, ibandronate either rapidly binds to bone or is excreted unchanged into urine.

Each 3ml Pre-filled syringe contains Ibandronate Sodium Monohydrate INN

3.3759 mg equivalent to Ibandronic acid 3 mg.

Osteoporosis is a condition where the body removes more bone than it replaces, leading to weaker bones that are more prone to fractures. This disease is common in women after menopause but can also affect men. Initially, osteoporosis has no symptoms, but it may cause a loss of height and increase the likelihood of fractures, especially in the spine, wrist, and hip.

Ibandronic acid works by inhibiting osteoclast activity, reducing bone resorption and turnover. In postmenopausal women, it decreases the elevated rate of bone turnover, resulting in a progressive increase in bone mass.

Bondrova i.v. is indicated for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures.

The recommended dose of Bondrova i.v. is 3 mg, administered as an intravenous injection over 15–30 seconds, every 3 months.

If a dose is missed, it should be administered as soon as possible, with subsequent doses scheduled every 3 months from the date of the last injection.

Special Dosage Instructions

Hepatic Impairment: No dosage adjustment required.

Renal Impairment: No dosage adjustment needed for patients with mild to moderate renal impairment (creatinine clearance ≥30 ml/min).

Elderly Patients: No dosage adjustment required.

Pediatric Patients: Bondrova i.v. is not recommended for use in pediatric patients.